Thrombus (Blood clot) formation is a process taken place when body is injured and bleeding. The process is activated by various stimulants such as coagulation system, activation of platelets and vascular endothelial damage1.
Thrombus formation may have serious consequences, which include cardiovascular and cerebra-vascular accidents such as myocardial infarction and stroke, as well as deep venous thrombosis (DVT) and pulmonary blockage1.
Thrombosis and related diseases are the one of the leading causes of mortality and disability worldwide. Therefore research and development of novel antithrombotic drugs are of scientific and clinical importance.
Berberine (BBR) is a natural compound isolated from therapeutic plants such as Coptis chinensis. It has various pharmacological activities and valuable efficacy against a variety of human diseases such as; endocrine and metabolic system diseases, digestive system, nervous system, cardiovascular system and reproductive system disorders2.
Prior studies have revealed that berberine inhibits platelet aggregation in experimental animals3 as well as in clinical studies4. The inhibitory effect of berberine on platelet aggregation is equivalent to that of aspirin. In several preclinical studies it has exposed to repress thrombus formation5.
Given that scientists wanted to explore the anticoagulant and antithrombotic properties of berberine in order to have some natural and safe therapeutic agents. So the effects of Berberine on the coagulation system are investigated using in vitro and in vivo models and the results show that BBR has anticoagulant activity when used to inhibit thrombus formation6.
Researchers conducted in vitro experiment and rabbits were used a model animal. They are divided into different groups with different specific treatments. After all experiments; whole blood clotting time (CT), activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen (FIB) and the activities of a series of coagulation factors and antithrombin-III (AT-III) were determined.
Metabolic parameters such as blood lipids and glucose were also assayed. In parallel experiments, the effect of Berberine (BBR) on inferior vena cava thrombus formation was determined by ligation.
It was found that berberine suppressed the activities of coagulation factors participating in the coagulation pathways. The berberine induced changes resulted in a significant inhibition in thrombus formation in the inferior vena cava. After treatment, BBR improved the metabolic parameters of the rats and effectively prevented the HFD-induced blood hypercoagulation.
Therefore it was established that the BBR has anticoagulant activity, which is responsible for its anti-thrombotic effect. The BBR may be suitable for the intervention of hypercoagulability and thrombosis when it is used to treat metabolic diseases.
Your email address will not be published. Required fields are marked *
26 May, 2019